Sonographic quantitative assessment of the deltoid muscle could translate into a dedicated, simple and noninvasive screening method to detect type 2 diabetes.
The quantitative assessment of the deltoid muscle by ultrasound could accurately detect type 2 diabetes, according to a study presented at the Radiological Society of North America (RSNA) 2021 Annual Meeting.
“Following further studies, this process could translate into a dedicated, simple and noninvasive screening method to detect type 2 diabetes,” the authors wrote. The process could help identify “some of the 232 million undiagnosed persons globally and could prove especially beneficial in screening of underserved and underrepresented communities.”
The findings were presented by Steven Bishoy Soliman, D.O., RMSK, a musculoskeletal radiologist at Henry Ford Hospital & Health System in Michigan.
A previous study by Dr. Soliman that included 137 patients found that the ultrasound appearance of the deltoid muscle in patients with diabetes differed from that in patients with obesity but without diabetes. In the latest study the researchers aimed to evaluate if the sonographic quantitative assessment of the deltoid muscle can be used to detect type 2 diabetes.
In the study, deltoid muscle ultrasound images from 124 patients were independently reviewed by three musculoskeletal radiologists. Patients were categorized as the following: obese type 2 diabetes, non-obese type 2 diabetes, obese non-type 2 diabetes, and non-obese non-type 2 diabetes, with 31 images in each category. The radiologists, who were blinded to the patient’s category, measured the grayscale pixel intensity of the deltoid muscle and humeral cortex to calculate a muscle/bone ratio for each patient. Over three weeks, the radiologists repeated measurements on a random 40 patients. Patient age, gender, race, body mass index, insulin usage and hemoglobin A1c level were analyzed and the difference among the four groups was compared. Inter- and intra-radiologist variability or agreement were also assessed
The results showed a statistically significant difference in muscle/bone ratios between the groups with the average ratios as follows: obese type 2 diabetes, 0.54 (P < .001); non-obese type 2 diabetes, 0.48 (P < .001); obese non- type 2 diabetes, 0.42 (P = .03); and non-obese non- type 2 diabetes, 0.35.
Further, excellent inter-observer agreement (ICC 0.87) and intra-observer agreements (ICC 0.92, 0.95, and 0.94) were found. The sensitivity for detecting type 2 diabetes was 80% with a specificity of 63%.
“Quantitative deltoid muscle ultrasound can detect type 2 diabetes with the potential for a highly sensitive noninvasive screening method,” the authors wrote.
For more coverage of RSNA 2021, click here.
Study: Contrast-Enhanced Mammography Changes Surgical Plan in 22.5 Percent of Breast Cancer Cases
December 7th 2023Contrast-enhanced mammography detected additional lesions in 43 percent of patients and led to additional biopsies in 18.2 percent of patients, over half of whom had malignant lesions, according to a study of over 500 women presented at the recent Radiological Society of North America (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
Study: Regular Mammography Screening Reduces Breast Cancer Mortality Risk by More than 70 Percent
November 30th 2023Consistent adherence to the five most recent mammography screenings prior to a breast cancer diagnosis reduced breast cancer death risk by 72 percent in comparison to women who did not have the mammography screening, according to new research findings presented at the annual Radiological Society of North America (RSNA) conference.
FDA Clears Magnetic Resonance Spectroscopy Platform for Non-Invasive Assessment of Brain Chemistry
November 29th 2023BrainSpec Core reportedly offers enhanced sensitivity for low-grade gliomas and may facilitate the diagnosis of conditions including Alzheimer’s disease, multiple sclerosis, and epilepsy.